

Alliance between Noile-Immune Biotech, Inc. and Rebirthel Co., Ltd. on PRIME allogeneic CAR-T Cell Therapy using Immune Cells induced from Pluripotent Stem Cells

Noile-Immune Biotech, Inc. (2-12-10 Shiba-Daimon, Minato-ku, Tokyo, President: Koji Tamada, hereinafter "Noile-Immune") and Rebirthel Co., Ltd. (Kamigyō-ku, Kyoto, hereinafter "Rebirthel") are pleased to announce that we have entered into a contract on collaborative research and commercialization of next-generation gene-modified immune cell therapy combining Rebirthel's technology for producing immune cells from pluripotent stem cells and Noile-Immune's PRIME (Proliferation-inducing and migration-enhancing) technology for adapting immune cell therapies such as those of CAR-T cells and TCR-T cells to solid cancer.

The technology for regenerating antigen-specific immune cells from pluripotent stem cells, the fundamental technology of Rebirthel, was developed based on the research results of Prof. Hiroshi Kawamoto, Director of Institute for Life and Medical Sciences, Kyoto University, who is the founder and chief technology advisor of Rebirthel. This technology is expected to offer new immunotherapies in allogeneic setting cell transplantation and to allow the therapeutic application of all immune-related diseases such as cancer.

PRIME technology, the fundamental technology of Noile-Immune, related to cancer immune cell therapies such as CAR-T cell therapy, was developed by Dr. Koji Tamada, the scientific founder and representative director of Noile-Immune and professor of Yamaguchi University Graduate School of Medicine. PRIME technology not only enhances the functions of gene-modified immune cells by producing cytokines and chemokines, but also improves the ability of patient's own immune systems to cope with cancer cells.

Dr. Tamada says, "I am very pleased to establish an alliance with Rebirthel which has innovative allogeneic immune cell technologies. In this project, we will combine PRIME technology of Noile-Immune with Rebirthel's technology for generating antigen-specific immune cells from pluripotent stem cells and develop allogeneic gene-modified immune cells. By combining of these Japan-origin technologies, I hope we will be able to develop highly universal, next-generation gene-modified immune cells that can exert therapeutic effects against solid cancers and to create therapies offered to more cancer patients. We aim to develop state-of-the-art cancer immunotherapies."

Mr. Masunori Kajikawa, President and CEO of Rebirthel also says, "I am delighted with this collaboration between Noile-Immune and Rebirthel as it truly embodies the concepts of "an era when we can overcome cancer" and "pioneering a new era of treating cancer." In order to eradicate cancer, it is the requirement to apply two parties' strategies to various solid cancers. In this collaboration project, we will develop a novel, next-generation, and highly universal immune cell therapy and advance it as a treatment to address unmet medical needs all over the world."

Under this alliance, Noile-Immune and Rebirthel will conduct collaborative research on allogeneic gene-modified immune cell therapy. Both parties have the right to commercialize the results obtained from this collaborative research and to receive royalties from each other under the contract. Further contract terms are not disclosed.

About Rebirthel

A bio-venture originating from Kyoto University, which was established by Professor Hiroshi Kawamoto, Director of Institute for Life and Medical Sciences, Kyoto University, with the vision of "pioneering a new era of treating cancer." Utilizing multiple own patented technologies, Rebirthel aims to provide a novel treatment-allogeneic immune cell therapy.

For more information, please visit <https://rebirthel.com/>.

About CAR-T cells

Chimeric antigen receptor T cells are T cell transfected with artificial chimeric antigen receptors that combine single-chain antibodies specific to cell-surface antigens in cancer with molecular signaling regions involved in activation of T cells.

About PRIME technology

A technology to enhance the function of genetically modified immune cells such as CAR-T cells and to activate the host's own immune cells. Noile-Immune has an exclusive right.

About pluripotent stem cells

A cell with the ability to differentiate into cells of various tissues and organs (pluripotency) and to self-proliferate (self-renewal ability)

Noile-Immune Biotech Inc., established as a university start-up, aims to contribute to the arrival of an era when we can overcome cancer through the next-generation cancer immunotherapies, centering on PRIME technology.

Contact for inquiries or additional information

2-12-10 Shiba-Daimon, Minato-ku, Tokyo 105-0012, Japan

Noile-Immune Biotech, Inc.

E-mail: ir@noile-immune.com